Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Revenue of Aytu BioPharma, Inc. (AYTU)
Revenue in 2024 (TTM): $81 M
According to Aytu BioPharma, Inc.'s latest financial reports the company's current revenue (TTM) is $81 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Aytu BioPharma, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2024 | $81 M | $54.59 M | $-1,012,000 | $-14,076,000 | $-15,844,000 |
| 2023 | $107.4 M | $66.63 M | $-3,514,000 | $-17,051,000 | $-17,050,000 |
| 2022 | $96.67 M | $52.28 M | $-27,957,000 | $-110,283,000 | $-108,780,000 |
| 2021 | $65.63 M | $29.2 M | $-29,039,000 | $-58,030,000 | $-58,290,000 |
| 2020 | $27.63 M | $20.08 M | $-12,207,000 | $-13,620,679 | $-13,620,000 |
| 2019 | $7.32 M | $5.12 M | $-14,119,570 | $-27,131,908 | $-47,166,950 |
| 2018 | $3.66 M | $1.61 M | $-15,252,944 | $-10,187,863 | $-10,187,863 |
| 2017 | $3.22 M | $1.8 M | $-18,131,175 | $-22,508,304 | $-22,508,304 |
| 2016 | $2.56 M | $1.61 M | $-21,813,809 | $-28,180,084 | $-28,180,084 |
| 2015 | $261.78 K | $173.67 K | $-7,514,118 | $-7,747,314 | $-7,723,404 |
| 2014 | $58.93 K | $58.93 K | $-52,709 | $-6,392,387 | $-5,578,690 |
| 2013 | $1.75 K | $50 K | $-47,472 | $-57,318 | $-57,318 |
| 2012 | $1.75 K | $1.75 K | $-50,206 | $-59,675 | $-59,675 |
| 2011 | $ | $ | $-126,856 | $-136,802 | $-136,802 |
| 2010 | $ | $ | $-47,282 | $-56,467 | $-60,270 |
| 2009 | $1.75 K | $1.75 K | $-47,539 | $-58,894 | $-58,894 |
| 2008 | $ | $ | $-47,469 | $-48,954 | $-57,173 |
| 2007 | $ | $ | $-40,470 | $-48,954 | $-48,954 |